

Riferimenti bibliografici

Squires RA, Crawford C, Marcondes M, Whitley N. 2024 guidelines for the vaccination of dogs and cats – compiled by the Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA). *J Small Anim Pract.* 2024;65(5):277-316. doi:10.1111/jsap.13718 (adattamento italiano a cura di P. Dall'Ara).

European Medicines Agency. EMA recommends authorisation of first veterinary vaccine using RNA technology. Comunicato del 17 aprile 2026. <https://www.ema.europa.eu/en/news/ema-recommends-authorisation-first-veterinary-vaccine-using-rna-technology>

European Medicines Agency. Rapporti pubblici di valutazione (EPAR) dei vaccini felini con RNA autoamplificante: parere del CVMP del 16 aprile 2026, procedura EMEA/V/C/006520, e relativo riassunto delle caratteristiche del prodotto.

Huisman W, Mommen A, Basten S, et al. Development of a New Feline Combination Vaccine Including a Novel RNA Particle Vaccine Against Feline Leukemia Virus. *Vaccines (Basel).* 2026;14(7):625. doi:10.3390/vaccines14070625

European Directorate for the Quality of Medicines & HealthCare. Monografia 1321, Feline leukaemia vaccine (inactivated), Farmacopea europea.

Carroll EL, Nawar N, Bourgeois M. Drivers, Barriers and Unmet Needs Affecting Feline Vaccination Compliance: Insights from a Global Survey of Cat Owners and Veterinarians. *Vet Sci.* 2026;13(7):646. doi:10.3390/vetsci13070646

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383:2603-2615. doi:10.1056/NEJMoa2034577

Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med.* 2021;384:403-416. doi:10.1056/NEJMoa2035389

Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis.* 2022;22:1293-1302. doi:10.1016/S1473-3099(22)00320-6

Wilson E, Goswami J, Baqui AH, et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. *N Engl J Med.* 2023;389:2233-2244. doi:10.1056/NEJMoa2307079

Ho NT, Hughes SG, Ta VT, et al. A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines. *NPJ Vaccines.* 2024;9:233. doi:10.1038/s41541-024-01017-5

European Medicines Agency. Rapporto pubblico di valutazione (EPAR) del vaccino anti-COVID-19 a mRNA autoamplificante (zapomeran); autorizzazione all'immissione in commercio nell'Unione europea del 12 febbraio 2025.

Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. *Lancet.* 2024;403:632-644. doi:10.1016/S0140-6736(23)02268-7